31 Jan 2011
The 16th SCI-RSC Medicinal Chemistry Symposium took place on 11-14 Sept 2011, in Cambridge.
Available Conference Papers:
- Programme/Flyer
- Discovery of next generation glucokinase activators, Mike Waring, AstraZeneca, UK
- The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist, Nigel Swain, Pfizer, UK
- A medicinal chemistry journey from almokalant to AZD7009/ AZD1305, discovery of clinical candidates for treatment of atrial fibrillation, Annika Björe, AstraZeneca, Sweden
- Lilly's open innovation drug discovery initiatives: from concept to reality, Marta Pineiro-Nunez, Lilly Research Laboratories, USA
- Cell-based optimization of novel antimalarials from HTS hit, Arnab Chatterjee, Genomics Institute of the Novartis Research Foundation, USA
- SAR and structural biology of NEK kinase inhibitors, Swen Hoelder, Cancer Research, UK
- CPHPC plus anti-SAP antibody: a first in class small molecule/antibody combination to eliminate systemic amyloid deposits, Mark Pepys, University College London, UK
- Now what? The state of drug discovery, Derek Lowe, Vertex, USA
- mGluR2 Positive allosteric modulators, Jose Cid, Janssen R&D, Spain
- Discovery of PF-3635659: an inhaled once-daily M3 antagonist for asthma and COPD, David Price, Pfizer, UK
- Orally active TLR7 agonists for antiviral application, David Pryde, Pfizer, UK
- Finding the Gini: brain penetrant kinase inhibitors for the treatment of neurodegenerative diseases, Piotr Graczyk, Eisai, UK
- KAT II Inhibitors; a Novel Approach for the Treatment of Schizophrenia, Jaclyn Henderson, Pfizer PharmaTherapeutics R&D, USA
Visit Blog